|Welcome to the Inserm Transfert website

… INSERM TRANSFERT, YOUR
PARTNER FOR VALUE CREATION
AND TECHNOLOGY TRANSFER

Inserm Transfert, specialised in technology transfer and life sciences, was founded in 2000.

It is the private subsidiary of Inserm under a Public Service Delegation agreement. The company supports Inserm research units and researchers in the process undertaken to create value from their work. Its actions are part of the translational continuum, from basic and technological to clinical research, and are used for the creation of economic and societal value.

 
 

Our
technology offer



Our strategic
innovation domains


lamp
1673

PATENT FAMILIES*

tube
15

MILLIONS OF EUROS INVESTED IN MATURATION

micro
400

NUMBER OF CONTRACTS AND LICENSES*

financial
281

PROJECTS DETECTED*

* For the year 2017

R&D PROJECTS

  • EE-ASI

    The EE-ASI project is an innovative ASI approach which combines technologies brought by academic partnerships and two SMEs.

  • EBOVAC 2

    The EBOVAC2 project is intended to assess the safety and efficacy of a new preventative vaccine regimen against EVD.

  • EBOLAMODRAD

    The overall objective of this project is to develop and provide rapid, ambulatory diagnostic tools which will considerably increase our […]

  • CARMMA

    CARMMA is based on the new hypothesis that the comorbidities of obesity are related premature senescence of adipose tissue (AT).

  • AGEDBRAINSYSBIO

    A European group of university laboratories and scientists working for industrial SME companies, combining integrated systems biology and comparative genomics […]

  • EHVA

    The aim of EHVA is to develop several innovative concepts in vaccines against HIV, both for prophylaxis and treatment.

  • ENSAT-HT

    This project will help to construct and assess a stratified health promotion programme based on so-called “omics” technologies for patients […]

  • ERINHA

    ERINHA is a research infrastructure intended to improve European preparation and response, in terms of research, to combat highly infectious […]

  • GENEGRAFT

    The aim of GENEGRAFT is to conduct a phase I/II clinical study on ex vivo gene therapy in 3 patients […]

  • JPND

    The European programme – “Research into neurodegenerative diseases” (JPND) is the largest worldwide research initiative intended to respond to the […]

  • MEDIT-AGEING

    The primary objectives of MEDIT-AGEING are to improve early detection of Alzheimer’s disease and the understanding of its pathophysiological mechanisms […]

  • METACARDIS

    METACARDIS is developing an approach to systemic medicine at several levels in order to identify biological relationships 

  • IMMUNOSCORE

    IMMUNOSCORE® measures the density of two T lymphocyte populations – CD8 and CD3 – which are found within and at […]

  • COHORTES

    INSERM TRANSFERT has developed unique expertise in the development and negotiation of public/private partnerships (PPP) linked to research projects involving […]

  • MEDIMMUNE

    Since 2011, MedImmune, the AstraZeneca international biological substances unit, has contributed to the advancement of Inserm laboratory research in several […]

  • SILTISS

    The Team run by Didier Letourneur, CNRS Research Director and Director of Inserm U1148, located in Paris and awarded the […]

WordPress Lightbox